| Full text | |
| Author(s): |
Alexsandra C. Malaquias
[1]
;
Lize V. Ferreira
[2]
;
Silvia C. Souza
[3]
;
Ivo J. P. Arnhold
[4]
;
Berenice B. Mendonça
[5]
;
Alexander A. L. Jorge
[6]
Total Authors: 6
|
| Affiliation: | [1] Universidade de São Paulo. Faculdade de Medicina. Laboratório de Hormônios e Genética Molecular LIM/42 - Brasil
[2] Universidade de São Paulo. Faculdade de Medicina. Laboratório de Hormônios e Genética Molecular LIM/42 - Brasil
[3] Universidade de São Paulo. Faculdade de Medicina. Laboratório de Hormônios e Genética Molecular LIM/42 - Brasil
[4] Universidade de São Paulo. Faculdade de Medicina. Laboratório de Hormônios e Genética Molecular LIM/42 - Brasil
[5] Universidade de São Paulo. Faculdade de Medicina. Laboratório de Hormônios e Genética Molecular LIM/42 - Brasil
[6] Universidade de São Paulo. Faculdade de Medicina. Laboratório de Hormônios e Genética Molecular LIM/42 - Brasil
Total Affiliations: 6
|
| Document type: | Journal article |
| Source: | Arquivos Brasileiros de Endocrinologia e Metabologia; v. 52, n. 5, p. 800-808, 2008-07-00. |
| Abstract | |
Noonan Syndrome (NS) is one of the most common genetic syndromes and it is an important differential diagnosis in children with short stature, delayed puberty and cryptorchidism. NS is characterized by dysmorphic facial features, congenital heart defects and short stature, but there is a great variability in phenotype. NS may occur in a pattern consistent with autosomal dominant inheritance with almost complete penetrance. The diagnosis is based on a clinical score system proposed by van der Burgt e cols. in 1994. In recent years, germline mutations in the components of RAS-MAPK (mitogen activated protein kinase) pathway have been shown to be involved in the pathogenesis of NS. Mutations in PTPN11, KRAS, SOS1, RAF1 e MEK1 can explain 60-70% of NS molecular cause. Growth hormone therapy is proposed to correct the short stature observed in these patients. Recent studies suggest that the presence of PTPN11 mutations in patients with NS indicates a reduced growth response to short-term hrGH treatment. In this article, it is reviewed clinical and molecular aspects of NS and hrGH treatment for short stature. (AU) | |